

Express Mail No. EV452775245US


**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

ATTY. DOCKET NO.

9471-011-999

(CAM: 209025-999010)

APPLICATION NO.

10/506,406

APPLICANT

Swiercz et al.

FILING DATE

March 14, 2005

GROUP

1653-1654

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
✓	A01	5,639,726	06/17/1997	Lawrence et al.			
✓	A02	6,303,338 B1	10/16/2001	Ni et al.			

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
✓	B01	WO 97/39028	10/23/1997	PCT		

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

✓	C01	International Search Report dated 1/14/2004 of corresponding PCT Application No. PCT/US03/06679.
	C02	Achbarou et al., Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 1994 May 1;54(9):2372-7.
	C03	Chorostowska-Wynimko et al., A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther. 2003 Jan;2(1):19-28.
	C04	Conese et al., The urokinase/urokinase-receptor system and cancer invasion. Baillieres Clin Haematol. 1995 Jun;8(2):365-89.
	C05	Danø et al., Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139-266.
	C06	Declerck et al., Measurement of plasminogen activator inhibitor I in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 1988 Jan;71(1):220-5.
	C07	Declerck et al., Purification and characterization of a plasminogen activator inhibitor I binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem. 1988 Oct 25;263(30):15454-61.
	C08	Ellis et al., Plasminogen activation by receptor-bound urokinase. Semin Thromb Hemost. 1991 Jul;17(3):194-200.
	C09	Festuccia et al., Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol Res. 1995;7(3-4):131-8.
	C10	Hajjar et al., Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem. 1990 Feb 15;265(5):2908-16.
	C11	Hekman et al., Bovine plasminogen activator inhibitor I: specificity determinations and comparison of the active, latent, and guanidine-activated forms. Biochemistry. 1988 Apr 19;27(8):2911-8.
	C12	Hekman et al., Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem. 1985 Sep 25;260(21):11581-7.
	C13	Hoylaerts et al., Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982 Mar 25;257(6):2912-9.
	C14	Hsueh et al., Molecular mechanisms in the hormonal regulation of plasminogen activator activity in ovarian granulosa cells and cumulus-oocyte complexes. Prog Clin Biol Res. 1988;267:227-57.
	C15	Jankun et al., Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem. 1993 Oct;53(2):135-44.
	C16	Jankun et al., Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res. 1997 Feb 15;57(4):559-63. Erratum in: Cancer Res 1998 Jan 1;58(1):179.
	C17	Jankun et al., Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator. Cancer Res. 1991 Feb 15;51(4):1221-6.
	C18	Kwaan et al., Components of the plasminogen-plasmin system in human tumor cell lines. Semin Thromb Hemost. 1991 Jul;17(3):175-82.
✓	C19	Lawrence et al., Engineering plasminogen activator inhibitor I mutants with increased functional stability.